Gut Bacteria Linked to Milder Pulmonary Arterial Hypertension in New Study

Pulmonary arterial hypertension is a disease with few good options: pressures in the lung's blood vessels climb relentlessly, forcing the right ventricle to work harder and harder until it fails. A prospective cohort study published in Comprehensive Physiology by researchers at the University of Cincinnati, the University of Minnesota, and Vanderbilt University now points to an unlikely player in that progression: the bacteria living in the gut. Specifically, the team found that patients with detectable Lactobacillus in their stool samples tended to have less severe pulmonary hemodynamics and less right ventricular dysfunction than those without it.

Lactobacillus Presence Linked to Less Severe Hemodynamics

The core finding is striking in its specificity. Patients with pulmonary arterial hypertension who carried Lactobacillus species in their gut microbiome showed more favorable pulmonary hemodynamic measurements at right heart catheterization, the gold-standard procedure for assessing how hard the right side of the heart is working against elevated lung pressures. The association extended to echocardiographic measures of right ventricular dysfunction, meaning the structural damage that PAH inflicts on the heart appeared less pronounced in those patients. That a single bacterial genus correlates with these downstream cardiopulmonary markers, not just with some intermediate biochemical signal, elevates the finding above the noise of many microbiome association studies.

The amino acid threonine reinforced the picture. Higher circulating threonine levels, measured in pulmonary artery blood using nuclear magnetic resonance metabolomics, were linked to more favorable hemodynamic characteristics in the prospective cohort. Crucially, those associations held up when the team tested them in a separate, independent validation cohort of PAH patients, making the threonine signal considerably more robust than a single-cohort observation.

Why This Matters for a Disease With Limited Treatment Options

PAH affects a relatively small but devastatingly ill population. As the NHLBI describes, the condition forces blood pressure in the lung vasculature above normal ranges, straining the heart and producing progressive shortness of breath, fatigue, and chest pain. Existing therapies target the vascular biology directly, vasodilating the pulmonary arteries, but none reverse the disease. Any modifiable factor that tracks with disease severity is therefore worth investigating seriously.

The gut has been gaining traction as one such factor. Prior evidence points to gut dysbiosis as a contributor to PAH progression, operating through mechanisms that include altered immune signaling and systemic inflammation. Work summarized by NIH-affiliated researchers has proposed that gut microbiota and their metabolites may worsen PAH through increased gut permeability, bacterial translocation, and shifts in metabolites such as short-chain fatty acids and trimethylamine N-oxide. What this new study adds is a more granular resolution: not just dysbiosis in the abstract, but a specific genus, Lactobacillus, pointing in a potentially protective direction, and a specific metabolite, threonine, tracking with better hemodynamics.

How Shotgun Metagenomics and NMR Metabolomics Framed the Analysis

The study's credibility rests heavily on its methodological choices. Rather than relying on 16S rRNA sequencing, which identifies microbes at a coarse taxonomic level, the team used shotgun metagenomics on stool samples, a technique that sequences all the DNA present and allows for more precise species-level identification. Simultaneously, pulmonary artery blood underwent nuclear magnetic resonance metabolomics, an approach that simultaneously profiles dozens of circulating metabolites without requiring prior hypotheses about which ones might matter.

Both measurements were collected while patients also underwent right heart catheterization, meaning the microbial, metabolic, and hemodynamic data all came from the same clinical window. The prospective cohort design strengthened the analysis by establishing that exposure data (who has Lactobacillus, what their threonine levels are) preceded the outcome assessments, minimizing the recall bias that plagues retrospective studies. Validation in an independent cohort then tested whether the threonine associations were reproducible, which they were.

Open Questions About Causality and Mechanism

What the study cannot tell us is whether Lactobacillus is doing something protective or simply surviving better in patients whose disease happens to be less severe for other reasons. Observational cohort studies establish associations, not causal relationships, and PAH is a multifactorial condition where confounding is difficult to exclude entirely. The precise mechanism connecting gut Lactobacillus to pulmonary hemodynamics remains unknown: does the bacterium produce metabolites that reach the pulmonary vasculature, dampen systemic inflammation, or strengthen the gut barrier in ways that prevent harmful bacterial translocation? The role of threonine is equally unclear. Threonine is an essential amino acid involved in mucin synthesis and immune function, but how its circulating levels in PAH patients connect to Lactobacillus abundance or to vascular stiffness is a question the current data cannot answer.

The study itself acknowledges the need for further investigation into the relationship between gut microbial Lactobacillus, circulating metabolites, disease severity, and clinical outcomes.

Microbiota Transplant Trials Could Test the Hypothesis Directly

If Lactobacillus or the metabolic environment it helps create genuinely moderates PAH severity, the therapeutic implication is that reshaping the gut microbiome could become an adjunct strategy. That hypothesis is already being tested: a placebo-controlled randomized trial at the University of Minnesota is currently assessing the safety, feasibility, and pharmacokinetics of microbiota transplant therapy with antibiotic preconditioning and fiber supplementation specifically in PAH patients. Results from that trial will help clarify whether deliberately altering the microbiome can move the hemodynamic needle, and whether findings like those in this new prospective cohort study reflect a genuine biological mechanism worth targeting.

For now, the Cincinnati-Minnesota-Vanderbilt team has added a precise, metagenomics-confirmed observation to a field that has often dealt in generalities: in PAH, having Lactobacillus in your gut correlates with a less battered heart and a less pressurized pulmonary vasculature. Whether that correlation becomes a therapy depends on the mechanistic and interventional work still ahead.